Chronic Nasopharyngitis
Conditions
Interventions
Patients with chronic nasopharyngitis will receive Epipharyngeal Abrasive Therapy (EAT) once a week for 4 weeks. Peripheral blood and epipharyngeal swab samples will be collected before and after the
Sponsors
Mogitate Medical Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants diagnosed with chronic nasopharyngitis, aged 15 years or older, who consent to EAT and understand the study purpose and provide written informed consent.
Exclusion criteria
Exclusion criteria: Individuals with severe systemic diseases, those using immunosuppressive agents, pregnant or breastfeeding women, or those deemed inappropriate by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in CD4/CD8 ratio in scraped epithelial cells and peripheral blood before and after EAT (evaluated at baseline and 3 months after treatment) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Th17/Treg ratio (baseline and 3 months) Transition of subjective symptom scores (VAS) at baseline, 1 month, and 3 months Change in endoscopic inflammatory findings (baseline and 3 months) Comparison of immune profiles with healthy controls | — |
Countries
Japan
Contacts
Public ContactManabu Mogitate
Mogitate Medical Corporation Mogitate ENT Clinic
Outcome results
None listed